111 related articles for article (PubMed ID: 1734217)
1. Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.
Feig SA; Krailo MD; Harris RE; Baum E; Holcenberg JS; Kaizer H; Steinherz L; Pendergrass TW; Saunders EF; Warkentin PL
Med Pediatr Oncol; 1992; 20(2):124-9. PubMed ID: 1734217
[TBL] [Abstract][Full Text] [Related]
2. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
3. Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study.
Buchanan GR; Rivera GK; Boyett JM; Chauvenet AR; Crist WM; Vietti TJ
Blood; 1988 Oct; 72(4):1286-92. PubMed ID: 3167209
[TBL] [Abstract][Full Text] [Related]
4. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
Koh KN; Im HJ; Kim H; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Yoo KH; Sung KW; Koo HH; Lim YT; Park JE; Park BK; Park HJ; Seo JJ
J Korean Med Sci; 2017 Apr; 32(4):642-649. PubMed ID: 28244291
[TBL] [Abstract][Full Text] [Related]
5. [Study of reinduction chemotherapy in bone marrow relapse of childhood acute lymphoblastic leukemia].
Sato Y; Ito R; Saito T; Suto Y; Tateoka N; Onodera N; Ikeda Y; Ito E; Miyano T; Tachibana N
Rinsho Ketsueki; 1989 Nov; 30(11):1923-30. PubMed ID: 2607611
[TBL] [Abstract][Full Text] [Related]
6. Intensive therapy for adult acute lymphoblastic leukemia: preliminary results of the idarubicin/vincristine/L-asparaginase/prednisolone regimen.
Bassan R; Battista R; Viero P; Pogliani E; Rossi G; Lambertenghi-Deliliers G; Rambaldi A; D'Emilio A; Buelli M; Borleri G
Semin Oncol; 1993 Dec; 20(6 Suppl 8):39-46. PubMed ID: 7507263
[TBL] [Abstract][Full Text] [Related]
7. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
[TBL] [Abstract][Full Text] [Related]
9. Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia.
Bassan R; Di Bona E; Lerede T; Pogliani E; Rossi G; D'Emilio A; Buelli M; Rambaldi A; Viero P; Rodeghiero F; Barbui T
Leuk Lymphoma; 1996 Jul; 22(3-4):295-301. PubMed ID: 8819079
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
[TBL] [Abstract][Full Text] [Related]
11. Improved treatment results in boys with overt testicular relapse during or shortly after initial therapy for acute lymphoblastic leukemia. A Pediatric Oncology group study.
Buchanan GR; Boyett JM; Pollock BH; Smith SD; Yanofsky RA; Ghim T; Wharam MD; Crist WM; Vietti TJ; Johnson W
Cancer; 1991 Jul; 68(1):48-55. PubMed ID: 2049752
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia.
Eguiguren JM; Pui CH
Med Pediatr Oncol; 1992; 20(1):58-60. PubMed ID: 1727213
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
14. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
[TBL] [Abstract][Full Text] [Related]
15. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
[TBL] [Abstract][Full Text] [Related]
16. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
17. Intensive therapy for adult acute lymphoblastic leukemia.
Berman E; Weiss M; Kempin S; Gee T; Bertino J; Clarkson B
Semin Hematol; 1991 Jul; 28(3 Suppl 4):72-5. PubMed ID: 1780756
[No Abstract] [Full Text] [Related]
18. Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: a Pediatric Oncology Group Study.
Buchanan GR; Rivera GK; Pollock BH; Boyett JM; Chauvenet AR; Wagner H; Maybee DA; Crist WM; Pinkel D
Cancer; 2000 Mar; 88(5):1166-74. PubMed ID: 10699908
[TBL] [Abstract][Full Text] [Related]
19. Reinduction therapy for advanced or refractory acute lymphoblastic leukemia of childhood.
Steinherz P; Meyers P; Wollner N; Redner A; Tan C
Cancer; 1989 Apr; 63(8):1472-6. PubMed ID: 2647273
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]